Aptose's Cash Dries Up, Going Concern Doubts Mount Amid Nasdaq Delisting

Ticker: APTOF · Form: 10-Q · Filed: Nov 13, 2025 · CIK: 882361

Sentiment: bearish

Topics: Biotechnology, Oncology, Going Concern, Nasdaq Delisting, Liquidity Crisis, Clinical Stage, Shareholder Deficit

TL;DR

**Aptose is on life support with dwindling cash and a Nasdaq delisting, making it a highly speculative bet for any investor.**

AI Summary

Aptose Biosciences Inc. reported no revenue for the three and nine months ended September 30, 2025, consistent with the prior year. The company incurred a net loss of $5.123 million for the three months ended September 30, 2025, an improvement from a $6.953 million net loss in the same period of 2024. For the nine months ended September 30, 2025, the net loss was $17.709 million, down from $23.845 million in 2024. Research and development expenses decreased significantly to $7.867 million for the nine months ended September 30, 2025, from $15.560 million in the prior year, while general and administrative expenses rose to $9.428 million from $8.510 million. Cash and cash equivalents plummeted to $613 thousand as of September 30, 2025, from $6.152 million at December 31, 2024. The company's accumulated deficit reached $558.676 million, and total shareholders' deficit expanded to $19.450 million. Aptose faces substantial doubt about its ability to continue as a going concern, citing insufficient cash to fund operations and reliance on advances from Hanmi, alongside its delisting from Nasdaq due to failure to meet the $2.5 million minimum equity requirement by March 31, 2025.

Why It Matters

Aptose's precarious financial state, marked by a mere $613 thousand in cash and a $19.450 million shareholders' deficit, signals extreme risk for investors. The delisting from Nasdaq due to failing the $2.5 million minimum equity requirement by March 31, 2025, severely limits its ability to raise capital, impacting its competitive standing against better-funded biotech firms. Employees face job insecurity, and customers (future patients) may see delays or cessation of drug development for critical hematologic cancers like those targeted by tuspetinib and luxeptinib. The broader market will view this as a cautionary tale for micro-cap biotechs struggling with clinical-stage development and capital access.

Risk Assessment

Risk Level: high — The company explicitly states "substantial doubt about the Company's ability to continue as a going concern" within one year after the financial statements' issue date. This is evidenced by cash and cash equivalents dropping from $6.152 million at December 31, 2024, to $613 thousand by September 30, 2025, and a negative shareholders' equity of $19.450 million. Furthermore, Aptose was delisted from Nasdaq for failing to meet the $2.5 million minimum equity requirement by March 31, 2025.

Analyst Insight

Investors should avoid APTOF given the severe going concern risk, minimal cash reserves of $613 thousand, and Nasdaq delisting. Existing shareholders should consider divesting, as the company's ability to secure necessary financing on acceptable terms is highly uncertain, potentially leading to further dilution or even liquidation.

Financial Highlights

debt To Equity
N/A
revenue
$0
operating Margin
N/A
total Assets
N/A
total Debt
N/A
net Income
-$5.123M
eps
N/A
gross Margin
N/A
cash Position
$613K
revenue Growth
0.0%

Revenue Breakdown

SegmentRevenueGrowth
Product Sales$00.0%

Key Numbers

Key Players & Entities

FAQ

What is Aptose Biosciences Inc.'s current cash position?

As of September 30, 2025, Aptose Biosciences Inc. had cash and cash equivalents of $613 thousand, a significant decrease from $6.152 million at December 31, 2024.

Why is Aptose Biosciences Inc. facing a 'going concern' warning?

Aptose Biosciences Inc. faces a 'going concern' warning due to insufficient cash to fund operations, an accumulated deficit of $558.676 million, and a negative shareholders' equity of $19.450 million as of September 30, 2025. The company also relies heavily on advances from Hanmi and was delisted from Nasdaq for failing to meet minimum equity requirements.

What was Aptose Biosciences Inc.'s net loss for the nine months ended September 30, 2025?

For the nine months ended September 30, 2025, Aptose Biosciences Inc. reported a net loss of $17.709 million, an improvement from the $23.845 million net loss in the same period of 2024.

Has Aptose Biosciences Inc. generated any revenue?

No, Aptose Biosciences Inc. reported no revenue for the three and nine months ended September 30, 2025, consistent with the prior year periods.

What happened with Aptose Biosciences Inc.'s Nasdaq listing?

Aptose Biosciences Inc. was delisted from The Nasdaq Stock Market for failing to gain compliance with Nasdaq's minimum equity requirement of $2.5 million by March 31, 2025.

How have Aptose Biosciences Inc.'s research and development expenses changed?

Research and development expenses for Aptose Biosciences Inc. decreased significantly to $7.867 million for the nine months ended September 30, 2025, from $15.560 million in the same period of 2024.

What are Aptose Biosciences Inc.'s primary drug candidates?

Aptose Biosciences Inc. has two clinical-stage investigational products for hematological malignancies: tuspetinib, an oral, potent myeloid kinase inhibitor, and luxeptinib, an oral, dual lymphoid and myeloid kinase inhibitor.

How much debt does Aptose Biosciences Inc. owe to related parties?

As of September 30, 2025, Aptose Biosciences Inc. had a non-current loan payable to a related party of $18.712 million, an increase from $10.000 million at December 31, 2024.

What was the impact of the reverse stock split on Aptose Biosciences Inc. shares?

On February 26, 2025, Aptose Biosciences Inc. effected a 1-for-30 reverse stock split of its issued and outstanding common shares. All common shares, stock options, and warrants have been retroactively adjusted to reflect this split.

What is Aptose Biosciences Inc.'s strategy to address its capital requirements?

Aptose Biosciences Inc. plans to raise additional funds through debt or other financing activities, including collaborations or reorganization to reduce operational expenses. However, management acknowledges there's no assurance of obtaining additional liquidity on acceptable terms, if at all.

Risk Factors

Industry Context

The biotechnology industry is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies often rely on external financing, including venture capital, debt, and equity offerings, to fund operations. The competitive landscape is intense, with many companies vying for breakthroughs in drug discovery and development.

Regulatory Implications

Aptose's delisting from Nasdaq due to failure to meet minimum equity requirements highlights the stringent financial oversight by stock exchanges. Companies must maintain compliance with listing standards to ensure continued trading and access to capital markets.

What Investors Should Do

  1. Monitor cash burn and runway closely.
  2. Evaluate the sustainability of Hanmi financing.
  3. Assess the impact of reduced R&D spending.
  4. Consider the implications of being delisted from Nasdaq.

Key Dates

Glossary

Going Concern
An accounting assumption that a business will continue to operate for the foreseeable future. If there is substantial doubt about this, it must be disclosed. (Aptose's financial condition raises substantial doubt about its ability to continue as a going concern.)
Accumulated Deficit
The total cumulative net losses of a company since its inception, less any cumulative net income. It represents a negative retained earnings balance. (Aptose's large and growing accumulated deficit of $558.676 million highlights its persistent unprofitability.)
Shareholders' Deficit
Occurs when a company's total liabilities exceed its total assets, resulting in negative equity. (Aptose's shareholders' deficit of $19.450 million indicates that its liabilities outweigh its assets.)
Reverse Stock Split
A corporate action where a company reduces the total number of its outstanding shares by consolidating them. This is often done to increase the share price. (Aptose implemented a reverse stock split to try and improve its share price, but it did not resolve its core financial issues.)
Related Party Transaction
A financial transaction between entities that are related to each other, such as between a parent company and its subsidiary, or between companies with common management or ownership. (Aptose's reliance on advances from Hanmi represents a related party transaction that is critical to its funding.)
Delisting
The removal of a stock or security from a stock exchange. This can happen for various reasons, including failure to meet listing requirements. (Aptose's delisting from Nasdaq due to not meeting equity requirements is a significant negative event.)

Year-Over-Year Comparison

For the nine months ended September 30, 2025, Aptose Biosciences Inc. reported a reduced net loss of $17.709 million compared to $23.845 million in the prior year, driven by a significant decrease in R&D expenses from $15.560 million to $7.867 million. However, G&A expenses increased from $8.510 million to $9.428 million. The company's financial position has severely deteriorated, with cash and cash equivalents plummeting to $613 thousand from $6.152 million at year-end 2024, and a worsening shareholders' deficit to $19.450 million. A major new risk is the delisting from Nasdaq due to failure to meet equity requirements.

Filing Stats: 4,431 words · 18 min read · ~15 pages · Grade level 17.5 · Accepted 2025-11-13 17:00:47

Filing Documents

—FINANCIAL INFORMATION

PART I—FINANCIAL INFORMATION 4

– Financial Statements

Item 1 – Financial Statements 4

– Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2 – Management's Discussion and Analysis of Financial Condition and Results of Operations 21

– Qualitative and Quantitative Disclosures about Market Risk

Item 3 – Qualitative and Quantitative Disclosures about Market Risk 40

– Controls and Procedures

Item 4 – Controls and Procedures 40

—OTHER INFORMATION

PART II—OTHER INFORMATION 41

– Legal Proceedings

Item 1 – Legal Proceedings 41

– Risk Factors

Item 1A – Risk Factors 41

– Exhibits

Item 6 – Exhibits 43

Signatures

Signatures 44 1 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Report contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995 and "forward-looking information" within the meaning of applicable Canadian securities law, which we collectively refer to as "forward-looking statements". Such forward-looking statements reflect our current beliefs and are based on information currently available to us. In some cases, forward-looking statements can be identified by terminology such as "may," "would," "could," "will," "should," "expect," "plan," "intend," "anticipate," "believe," "estimate," "predict," "potential," "continue," "hope," "foresee" or the negative of these terms or other similar expressions concerning matters that are not historical facts. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements that may be expressed or implied by such forward-looking statements, including, among others: our ability to continue as a going concern; our need to raise substantial additional capital in the near future and our ability to raise such funds when needed and on acceptable terms; if a financing is completed, it may not be a large enough financing to fully fund the company's operations; our suppliers or clinical sites may choose to implement work stoppage on key programs, change the terms of contracts or terminate contracts for key programs; our conversations with partners to renegotiate existing product license agreements may not be successful; our lack of product revenues and net losses and a history of operating losses; our ability to meet the continued listing requirements of the TSX and the listing requirements to relist on The Nasdaq Stock Market (the "Nasdaq"); our early stage of development, particularly the inherent risks and uncertainties associated with (i) develop

—FINANCIAL INFORMATION

PART I—FINANCIAL INFORMATION

– FINA NCIAL STATEMENTS

ITEM 1 – FINA NCIAL STATEMENTS Condensed Consolidated Interim Financial Statements (Unaudited) APTOSE BIOSCIENCES INC. For the three and nine months ended September 30, 2025 and 2024 4 APTOSE BIOSCIENCES INC. Condensed Consolidated Interim Statements of Financial Position (Expressed in thousands of US dollars, except for common share data) (unaudited) September 30, 2025 December 31, 2024 Assets Current assets: Cash and cash equivalents $ 613 $ 6,152 Restricted cash and restricted cash equivalents 1,024 555 Prepaid expenses 2,013 2,253 Other current assets 127 570 Total current assets 3,777 9,530 Non-current assets: Property and equipment, net 8 26 Right-of-use assets, operating leases 277 571 Other long-term assets 2,279 — Total non-current assets 2,564 597 Total assets $ 6,341 $ 10,127 Liabilities and Shareholders' Deficit Current liabilities: Accounts payable $ 1,456 $ 1,258 Accrued liabilities 4,804 2,773 Current portion of lease liability, operating leases 305 428 Interest on related party loan payable 514 18 Total current liabilities 7,079 4,477 Non-current liabilities: Lease liability, operating leases — 193 Loan payable to related party 18,712 10,000 Total non-current liabilities 18,712 10,193 Total liabilities 25,791 14,670 Shareholders' deficit: Share capital: Common shares, no par value, unlimited authorized shares, 2,552,429 and 2,006,028 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively 459,771 457,404 Additional paid-in capital 83,771 83,336 Accumulated other comprehensive loss ( 4,316 ) ( 4,316 ) Accumulated deficit ( 558,676 ) ( 540,967 ) Total shareholders' deficit ( 19,450 ) ( 4,543 ) Total liabilities and shareholders' deficit $ 6,341 $ 10,127 The accompanying notes are an integral part of thes

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing